NCT04895436 2026-02-09
ReVenG
AbbVie
Phase 2 Recruiting
Clinical Trials
4 trialsNCT06108232 2025-12-19
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03322865 2025-04-04
Obinutuzumab in Marginal Zone Lymphoma
University of Ulm
Phase 2 Active not recruiting
NCT02371590 2018-02-23
Lenalidomide and Obinutuzumab for Previously Untreated CLL
University of California, San Diego
Phase 2 Withdrawn